Patient Profile Presentation: A 48-Year-Old Man Presenting with a Right Renal Mass

Video

Shawnta Anakwah, MD, presents the patient profile of a 48-year-old man with advanced renal cell carcinoma presenting with a right renal mass.

Arnab Basu, MD: Let’s move on to our second case. Dr Anakwah, you have a second case to present.

Shawnta Anakwah, MD: This is a 48-year-old man who presented with a right renal mass. He went for a right radical nephrectomy and a renal vein thrombectomy. His pathology at the time of resection showed a T3 lesion, 10 cm in diameter. The tumor was grade 4, with both rectal and sarcomatoid features with extensive necrosis. However, he did have high PD-L1 expression at 90%. He was followed with CT scans by his urology provider. At his 3-month CT scan he had a new, tiny pulmonary nodule that was less than 1 cm. At 6 months, he had an additional nodule with a slight increase in the previous nodule. At his 9-month scan, he had increase in both nodules with a third new lesion. One lesion was biopsied and confirmed as metastatic RCC [renal cell carcinoma].

His labs on presentation were pretty unremarkable, with normal white blood cell, hemoglobin, and platelet counts; calcium was normal. He was deemed to be intermediate risk based on the fact that he had metastatic disease within 1 year of his nephrectomy. The decision was made to proceed with ipilimumab and nivolumab. After cycle 2 on day 9 of dual immunotherapy, the patient developed severe headache with fever, which was 10 of 10. He also had photophobia with severe nausea and vomiting, so he was sent to the emergency department. He was found to have a fever of 101.6. He had tachycardia. His blood pressure was 101/67, with an oxygen saturation of 95%.

His labs showed that new transaminitis. His cortisol level was elevated at 25.8 µg/dL. His TSH [thyroid stimulating hormone] was suppressed at 0.05 U/mL, and his fT4 was elevated at 4.5 ng/dL. An MRI of the brain, with or without contrast, showed an enhancing, enlarged pituitary gland with thickening of the pituitary stalk. Those findings that are seen in the setting of immune checkpoint inhibitor–associated hypophysitis.

He was started empirically on 1.5 mg/kg of prednisone and had immediate improvement in all his symptoms. After the steroids and liver test normalized, his TSH increased, his fT4 dropped, and he was continued on steroid taper over about 6 weeks. He was managed in combination with endocrinology and was placed on testosterone, hydrocortisone, and levothyroxine supplementation. The patient consented to rechallenge with the single-agent PD-L1 inhibitor. On his scans at the initiation of nivolumab, he was confirmed to have had a partial remission [PR]. The patient is now about 10 months out from treatment and still maintaining his PR with no evidence of disease progression.

Transcript edited for clarity.

Related Videos
Samer A. Srour, MB ChB, MS
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Samer A. Srour, MB ChB, MS
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Benjamin Garmezy, MD
Samer A. Srour, MB ChB, MS
Wenxin (Vincent) Xu, MD,
Related Content
Paul V. Viscuse, MD, of the University of Virginia

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

April 22nd 2024
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
Professor Jun Guo, MD, PhD, from Peking University Cancer Hospital

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

April 9th 2024
Article
Kyle A. Blum, MD, MS

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022
Podcast
Shankar Siva, PhD, MBBS, FRANZCR, Peter MacCallum Cancer Centre

SABR Leads to Local Control in Primary RCC Without Surgery

April 3rd 2024
Article
John McGrane, MD, consultant oncologist, Royal Cornwall Hospitals NHS Trust

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024
Article